# Comparison of the effects of drug-coated balloon and bare metal stent in the treatment of lower extremity arteriosclerosis obliterans

## TL;DR

This study compares drug-coated balloons and bare metal stents for treating leg artery disease, finding drug-coated balloons more effective in improving blood flow and long-term results.

## Contribution

Demonstrates that drug-coated balloons outperform bare metal stents in vascular function and one-year patency for lower extremity arteriosclerosis obliterans.

## Key findings

- Drug-coated balloons improved ankle-brachial index and endothelial function markers compared to bare metal stents.
- Drug-coated balloons showed higher one-year patency rates than bare metal stents.
- No significant difference in complication rates between the two treatments.

## Abstract

To compare the efficacy of drug-coated balloons (DCB) and bare metal stents (BMS) in treating lower extremity arteriosclerosis obliterans (LEASO).

Clinical data of 83 patients who underwent LEASO angioplasty with DCB or BMS at the Third Affiliated Hospital of Qiqihar Medical College from July 2021 to January 2024 were retrospectively analyzed. Patients were divided into the DCB (n=43) and BMS (n=40) groups based on the treatment method. Changes in ankle-brachial index (ABI), pulse volume recording (PVR), vascular endothelial function indicators, incidence of complications, and patency rate were compared between the two groups.

Three months after the surgery, the ABI and nitric oxide (NO) levels in the DCB group were higher, while the upstroke time (UT), percentage of mean arterial pressure (%MAP), brachial-ankle pulse wave velocity (baPWV), and endothelin-1 (ET-1) levels were lower than those in the BMS group (P<0.05). There was no significant difference in the incidence of complications between the two groups (P>0.05). One year after the surgery, the patency rate of the DCB group was higher than that of the BMS group (P<0.05).

DCB treatment for LEASO is superior to BMS in improving vascular function, protecting endothelial function, and achieving a one-year patency rate.